open access

Vol 2, No 1 (2011)
Case report
Published online: 2011-03-24
Get Citation

Efficacy of rituximab in refractory primary immune thrombocytopenia

Agnieszka Kopacz
Hematologia 2011;2(1):88-91.

open access

Vol 2, No 1 (2011)
CASE REPORTS
Published online: 2011-03-24

Abstract

This paper presents the case report of efficient use of rituximab in the treatment of refractory primary immune thrombocytopenia (ITP). Despite initial response to corticosteroids, most adults relapse during corticosteroid taper. Splenectomy should be taken into consideration in such situations. Those whom splenectomy fails to cure present a therapeutic challenge. Subsequent management usually involves some form of chronic immune suppression which, however, has serious side effects. The case of patient with refractory ITP, who achieved increased platelet counts and then the remission of disease after treatment with rituximab, is discussed in this paper.
Hematologia 2011; 2, 1: 88–91

Abstract

This paper presents the case report of efficient use of rituximab in the treatment of refractory primary immune thrombocytopenia (ITP). Despite initial response to corticosteroids, most adults relapse during corticosteroid taper. Splenectomy should be taken into consideration in such situations. Those whom splenectomy fails to cure present a therapeutic challenge. Subsequent management usually involves some form of chronic immune suppression which, however, has serious side effects. The case of patient with refractory ITP, who achieved increased platelet counts and then the remission of disease after treatment with rituximab, is discussed in this paper.
Hematologia 2011; 2, 1: 88–91
Get Citation

Keywords

primary immune thrombocytopenia; refractory; treatment; rituximab

About this article
Title

Efficacy of rituximab in refractory primary immune thrombocytopenia

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 1 (2011)

Article type

Case report

Pages

88-91

Published online

2011-03-24

Bibliographic record

Hematologia 2011;2(1):88-91.

Keywords

primary immune thrombocytopenia
refractory
treatment
rituximab

Authors

Agnieszka Kopacz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.